qSOFA联合suPAR用于急诊早期风险识别并指导抗生素治疗:一项随机对照试验
该研究分两部分:前瞻性队列分析suPAR联合qSOFA的早期风险识别价值,随后双盲RCT SUPERIOR(2018年11月至2020年12月)评估suPAR指导的医疗干预。急诊连续入组疑似感染、qSOFA=1且suPAR≥12 ng/mL的患者,随机接受单次安慰剂或美罗培南输注。主要终点为24小时内SOFA评分至少升高1分的早期恶化,安慰剂组40.4%(19例)vs美罗培南组15.9%(7例),差异24.5%(5.9-40.8),OR 0.14(0.04-0.50)。以qSOFA=1且suPAR<12 ng/mL为参照,qSOFA=1且suPAR≥12 ng/mL的28天死亡HR为2.98(95%CI 2.11-3.96)。
要点
- 急诊疑似感染、qSOFA=1且suPAR≥12 ng/mL的患者,28天死亡HR为2.98(95%CI 2.11-3.96),参照为qSOFA=1且suPAR<12 ng/mL。
- SUPERIOR试验中,安慰剂组24小时内SOFA恶化40.4%(19例)vs美罗培南组15.9%(7例),差异24.5%(5.9-40.8),OR 0.14(0.04-0.50)。
- 该RCT因大流行相关急诊资源重新分配而提前终止,仅入组91例(安慰剂47例、美罗培南44例)。
- 事后分析显示,72小时和96小时后SOFA评分中位变化分别为0和-1。
- qSOFA=1且suPAR<12 ng/mL的患者死亡风险接近参照水平,qSOFA=1合并suPAR≥12 ng/mL者风险升高。
适用人群与场景
- 急诊连续入组的疑似感染患者,qSOFA=1且suPAR≥12 ng/mL。
诊断标准与关键阈值
- qSOFA评分1分(原文指出qSOFA 2或3分者按脓毒症指南立即开始复苏,qSOFA 1分的解读仍有争议)。
- suPAR阈值12 ng/mL:suPAR≥12 ng/mL为高危组,suPAR<12 ng/mL为参照组。
处置流程与药物剂量
- 对急诊疑似感染、qSOFA=1且suPAR≥12 ng/mL的患者,随机给予单次安慰剂或美罗培南输注(原文未写明美罗培南剂量)。
研究设计与关键结果
- 研究分两部分:前瞻性队列分析suPAR联合qSOFA的早期风险识别;双盲RCT SUPERIOR评估suPAR指导的医疗干预,时间为2018年11月至2020年12月。
- 前瞻性队列采用多因素逐步Cox回归;RCT采用单因素和多因素logistic回归。
- 以qSOFA=1且suPAR<12 ng/mL为参照,qSOFA=1且suPAR≥12 ng/mL的28天死亡HR为2.98(95%CI 2.11-3.96);大部分死亡风险集中于qSOFA 2和3分的患者。
- RCT因大流行相关急诊资源重新分配提前终止,共入组91例:安慰剂组47例,美罗培南组44例。
- 主要终点(24小时内SOFA评分至少升高1分)在安慰剂组40.4%(n=19)和美罗培南组15.9%(n=7)发生,差异24.5%(5.9-40.8),OR 0.14(0.04-0.50)。
- 事后分析显示,72小时和96小时后SOFA评分中位变化分别为0和-1。
证据类型、等级与局限
- 证据类型:前瞻性队列研究加双盲随机对照试验(RCT)。
- 局限:RCT因大流行相关急诊资源重新分配而提前终止,仅入组91例。
对床旁实践的改变
- 对于急诊疑似感染且qSOFA=1的患者,联合检测suPAR有助于改善预后判断,并可能帮助决定更早治疗(作者认为)。
- qSOFA=1且suPAR≥12 ng/mL的患者接受单次美罗培南输注后24小时内SOFA恶化比例低于安慰剂组(40.4% vs 15.9%)。
指南或共识出处
- 脓毒症指南建议对qSOFA 2或3分的患者立即开始复苏(原文引用,未注明具体指南名称)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Sepsis guidelines suggest immediate start of resuscitation for patients with quick Sequential Organ Failure Assessment (qSOFA) 2 or 3. However, the interpretation of qSOFA 1 remains controversial. We investigated whether measurements of soluble urokinase plasminogen activator receptor (suPAR) may improve risk detection when qSOFA is 1.
METHODS: The study had two parts. At the first part, the combination of suPAR with qSOFA was analyzed in a prospective cohort for early risk detection. At the second part, the double-blind, randomized controlled trial (RCT) SUPERIOR evaluated the efficacy of the suPAR-guided medical intervention. SUPERIOR took place between November 2018 and December 2020. Multivariate stepwise Cox regression was used for the prospective cohort, while univariate and multivariate logistic regression was used for the RCT. Consecutive admissions at the emergency department (ED) with suspected infection, qSOFA 1 and suPAR ≥ 12 ng/mL were allocated to single infusion of placebo or meropenem. The primary endpoint was early deterioration, defined as at least one-point increase of admission Sequential Organ Failure Assessment (SOFA) score the first 24 h.
RESULTS: Most of the mortality risk was for patients with qSOFA 2 and 3. Taking the hazard ratio (HR) for death of patients with qSOFA = 1 and suPAR < 12 ng/mL as reference, the HR of qSOFA = 1 and suPAR ≥ 12 ng/mL for 28-day mortality was 2.98 (95% CI 2.11-3.96). The prospective RCT was prematurely ended due to pandemia-related ED re-allocations, with 91 patients enrolled: 47 in the placebo and 44 in the meropenem arm. The primary endpoint was met in 40.4% (n = 19) and 15.9% (n = 7), respectively (difference 24.5% [5.9-40.8]; odds ratio 0.14 [0.04-0.50]). One post hoc analysis showed significant median changes of SOFA score after 72 and 96 h equal to 0 and - 1, respectively.
CONCLUSIONS: Combining qSOFA 1 with the biomarker suPAR improves its prognostic performance for unfavorable outcome and can help decision for earlier treatment. Trial registration EU Clinical Trials Register (EudraCT, 2018-001008-13) and Clinical-Trials.gov (NCT03717350). Registered 24 October 2018.
参考来源
- Adami ME, Kotsaki A, Antonakos N, et al. qSOFA combined with suPAR for early risk detection and guidance of antibiotic treatment in the emergency department: a randomized controlled trial. Crit Care. 2024. PMID: 38321472. doi:10.1186/s13054-024-04825-2
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。